Skip to content

Erasca, Inc. ERAS Total Current Liabilities

Total Current Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$19.16B-20.4%
Eli Lilly logo
Eli LillyLLY
$36.63B+21.8%
Pfizer logo
PfizerPFE
$34.35B-5.8%
Amgen logo
AmgenAMGN
$24.96B+8.5%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$289.6M+82.6%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$14.33M-60.1%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.25B+1,196%
Enterprise value$4.25B+1,265%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s total current liabilities?
Erasca, Inc. (ERAS) reported total current liabilities of $26.66M in Q1 2026.
How has Erasca, Inc.'s total current liabilities changed year-over-year?
Erasca, Inc.'s total current liabilities increased by 4.7% year-over-year, from $25.47M to $26.66M.
What is the long-term trend for Erasca, Inc.'s total current liabilities?
Over 5 years (2020 to 2025), Erasca, Inc.'s total current liabilities has grown at a 15.8% compound annual growth rate (CAGR), from $13.68M to $28.51M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.